Clinical Research Directory
Browse clinical research sites, groups, and studies.
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Summary
Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therapeutic advances, neurotoxicity from standard treatments (resection, radiotherapy, chemotherapy) and the need for long-term care remain challenges. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), approved for breast cancer, show potential in other tumors, but their efficacy in MB is unclear. Treatment resistance is a concern. This project aims to identify genetic markers of sensitivity to CDK4/6 inhibitors in MB, to improve therapies and overcome resistance.
Key Details
Gender
All
Age Range
0 Years - 18 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-11-25
Completion Date
2026-08-31
Last Updated
2025-05-07
Healthy Volunteers
No
Conditions
Interventions
CDK4/6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib)
Evaluation of the response to CDK4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib) on selected Medulloblastoma (MB) patient-derived organoids (PDOs).
Locations (1)
Fondazione Policlinico Gemelli Irccs
Roma, ROMA, Italy